Literature DB >> 23211853

Non-alcoholic fatty liver disease and obesity: not all about body mass index.

Mangesh R Pagadala, Arthur J McCullough.   

Abstract

Patients with nonalcoholic fatty liver (NAFLD) are typically obese and confounded by the metabolic syndrome. The body mass index (BMI) is often used as a surrogate marker of obesity defined as a BMI >30 λkg/m(2). However, it is now apparent that it is the distribution of body fat (not total fat) that is associated with NAFLD. Many patients (as many as 25%) with NAFLD are nonobese. This is particularly true in Asians who have a significantly increased risk of cardiovascular disease and diabetes even among those with a normal BMI. It is important for clinicians to be aware that these "metabolically obese" NAFLD patients should be monitored for the metabolic syndrome and its associated adverse outcomes irrespective of their BMI.

Entities:  

Mesh:

Year:  2012        PMID: 23211853     DOI: 10.1038/ajg.2012.320

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

1.  SCAP gene polymorphisms decrease the risk of nonalcoholic fatty liver disease in females with metabolic syndrome.

Authors:  Shanshan Sun; Miao Wang; Haiyan Song; Tao Wu; Huafeng Wei; Songhua He; Zhaoguo Ding; Guang Ji
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

2.  Interactions of central obesity with rs3918242 on risk of non-alcoholic fat liver disease: a preliminary case-control study.

Authors:  Pengbo Wu; Yonglong Hua; Shiyun Tan; Ming Li; Yongxiang Shu; Guo Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

3.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012.

Authors:  Kenichi Nishioji; Yoshio Sumida; Mai Kamaguchi; Naomi Mochizuki; Masao Kobayashi; Takeshi Nishimura; Kanji Yamaguchi; Yoshito Itoh
Journal:  J Gastroenterol       Date:  2014-03-12       Impact factor: 7.527

4.  De novo synthesis of steroids and oxysterols in adipocytes.

Authors:  Jiehan Li; Edward Daly; Enrico Campioli; Martin Wabitsch; Vassilios Papadopoulos
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

5.  The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals.

Authors:  Kenichi Nishioji; Naomi Mochizuki; Masao Kobayashi; Mai Kamaguchi; Yoshio Sumida; Takeshi Nishimura; Kanji Yamaguchi; Hiroshi Kadotani; Yoshito Itoh
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

6.  Update of liver fibrosis and steatosis with transient elastography (Fibroscan).

Authors:  Grace Lai-Hung Wong
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-03-26

7.  High intensity interval training improves liver and adipose tissue insulin sensitivity.

Authors:  Katarina Marcinko; Sarah R Sikkema; M Constantine Samaan; Bruce E Kemp; Morgan D Fullerton; Gregory R Steinberg
Journal:  Mol Metab       Date:  2015-10-09       Impact factor: 7.422

8.  Homeostatic theory of obesity.

Authors:  David F Marks
Journal:  Health Psychol Open       Date:  2015-06-29

9.  Estimation of diagnosis and treatment costs of non-alcoholic Fatty liver disease: a two-year observation.

Authors:  Mohammad Ebrahim Ghamar Chehreh; Mohsen Vahedi; Mohammad Amin Pourhoseingholi; Sara Ashtari; Hossein Khedmat; Mohsen Amin; Mohammad Reza Zali; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2013-05-08       Impact factor: 0.660

10.  Non-Invasive Electrical Impedance Tomography for Multi-Scale Detection of Liver Fat Content.

Authors:  Yuan Luo; Parinaz Abiri; Shell Zhang; Chih-Chiang Chang; Amir H Kaboodrangi; Rongsong Li; Ashish K Sahib; Alex Bui; Rajesh Kumar; Mary Woo; Zhaoping Li; René R Sevag Packard; Yu-Chong Tai; Tzung K Hsiai
Journal:  Theranostics       Date:  2018-02-08       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.